报价延迟最少15分钟:2026/03/29 02:08 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.97 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-7.13/1.95
|
|
企业价值
3.30B
|
| 资产负债 |
|
每股账面净值
10.86
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.20B
|
|
每股收益
10.55
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases. |
